Altimmune, Inc. (ALT) vs Prime Medicine, Inc. (PRME)
Altimmune, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Altimmune, Inc. and Prime Medicine, Inc. are of similar size ($609.4M and $593.3M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −17.9%. Altimmune, Inc. has the higher net margin (0.00% vs −4,613.1%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 16 metrics below, Altimmune, Inc. leads on 11 and Prime Medicine, Inc. on 5.
Valuation
Profitability
| Metric | ALT | PRME | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (4,824.94%) | 0.00% |
| Net margin | 0.00% | (4,613.11%) | 0.00% |
| Free cash flow margin | 0.00% | (3,850.92%) | 0.00% |
| Return on equity | (28.87%) | (373.29%) | (57.72%) |
| Return on assets | (25.58%) | (71.16%) | (49.22%) |
| Return on invested capital | (34.30%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack